CytoDyn Inc.
CYDY
$0.2265
$0.022511.03%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -100.00% |
| Gross Profit | -- | -- | -- | -- | 100.00% |
| SG&A Expenses | -19.94% | -9.95% | -28.06% | -37.04% | -57.29% |
| Depreciation & Amortization | -48.57% | -50.00% | -72.09% | -83.43% | -87.89% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.10% | 3.77% | -54.92% | -55.50% | -86.88% |
| Operating Income | -11.10% | -3.77% | 54.92% | 55.50% | 86.88% |
| Income Before Tax | 86.29% | 73.35% | 72.95% | 37.56% | 64.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 86.29% | 73.35% | 72.95% | 37.56% | 64.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 86.29% | 73.35% | 72.95% | 37.56% | 64.43% |
| EBIT | -11.10% | -3.77% | 54.92% | 55.50% | 86.88% |
| EBITDA | -11.24% | -3.91% | 54.87% | 55.37% | 86.87% |
| EPS Basic | 84.63% | 72.22% | 72.77% | 49.67% | 71.94% |
| Normalized Basic EPS | 47.37% | 48.62% | 62.86% | 65.90% | 78.89% |
| EPS Diluted | 83.57% | 72.54% | 72.99% | 51.02% | 72.34% |
| Normalized Diluted EPS | 47.77% | 48.97% | 63.09% | 65.90% | 78.89% |
| Average Basic Shares Outstanding | 21.71% | 19.96% | 17.45% | 15.89% | 19.90% |
| Average Diluted Shares Outstanding | 23.39% | 21.71% | 19.26% | 15.89% | 19.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |